Author details

Full Name

Daniel Zingg

Affiliation

Netherlands Cancer Institute

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37642941	MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.	J Exp Med	2023
37642941	MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.	J Exp Med	2023
36050473	Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.	Nature	2022
36050473	Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.	Nature	2022
32117586	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.	Oncoimmunology	2020
32117586	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.	Oncoimmunology	2020
31039140	SMAD signaling promotes melanoma metastasis independently of phenotype switching.	J Clin Invest	2019
31039140	SMAD signaling promotes melanoma metastasis independently of phenotype switching.	J Clin Invest	2019
30951662	Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation.	Cell Stem Cell	2019
30951662	Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation.	Cell Stem Cell	2019
28737469	Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).	Expert Rev Pharmacoecon Outcomes Res	2018
28898550	Rare, yet relevant tumor cells - A new twist to melanoma cell plasticity.	Pigment Cell Melanoma Res	2018
28737469	Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT).	Expert Rev Pharmacoecon Outcomes Res	2018
30008323	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.	Cancer Cell	2018
30008323	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.	Cancer Cell	2018
28898550	Rare, yet relevant tumor cells - A new twist to melanoma cell plasticity.	Pigment Cell Melanoma Res	2018
28746871	The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.	Cell Rep	2017
28746871	The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.	Cell Rep	2017
27903862	Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.	Sci Transl Med	2016
27903862	Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.	Sci Transl Med	2016
25609585	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.	Nat Commun	2015
25885555	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.	Genome Biol	2015
25629959	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.	PLoS Genet	2015
25609585	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.	Nat Commun	2015
25885555	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.	Genome Biol	2015
25629959	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.	PLoS Genet	2015
22772081	Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.	Nat Cell Biol	2012
22772081	Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.	Nat Cell Biol	2012
21239582	Sulfate-driven elemental sparing is regulated at the transcriptional and posttranscriptional levels in a filamentous cyanobacterium.	J Bacteriol	2011
21239582	Sulfate-driven elemental sparing is regulated at the transcriptional and posttranscriptional levels in a filamentous cyanobacterium.	J Bacteriol	2011
18086371	Responsiveness of fibrocytes to toll-like receptor danger signals.	Immunobiology	2007
18086371	Responsiveness of fibrocytes to toll-like receptor danger signals.	Immunobiology	2007
15064712	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.	Oncogene	2004
27137923	Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).	Strahlenther Onkol	2004
15289348	Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.	Cancer Res	2004
15064712	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.	Oncogene	2004
14751504	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?	Int J Radiat Oncol Biol Phys	2004
27137923	Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).	Strahlenther Onkol	2004
15289348	Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.	Cancer Res	2004
14751504	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?	Int J Radiat Oncol Biol Phys	2004
12678723	Signal transduction inhibitors as radiosensitizers.	Curr Med Chem Anticancer Agents	2002
12678723	Signal transduction inhibitors as radiosensitizers.	Curr Med Chem Anticancer Agents	2002
11157943	One of two hemN genes in Bradyrhizobium japonicum is functional during anaerobic growth and in symbiosis.	J Bacteriol	2001
11719451	The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.	Cancer Res	2001
11157943	One of two hemN genes in Bradyrhizobium japonicum is functional during anaerobic growth and in symbiosis.	J Bacteriol	2001
11719451	The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.	Cancer Res	2001

1 - 46 of 46

Shruthy Suresh

Memorial Sloan Kettering Cancer Center

Career Start Year 2013

Number of shared co-authors 0

Manoela Tiago

Thomas Jefferson University

Career Start Year 2011

Number of shared co-authors 4

Aleksandra M Michalowski

Center for Cancer Research, National Cancer Institute

Career Start Year 2010

Number of shared co-authors 5

Juan L Callejas-Valera

Cancer Biology Research Center

Career Start Year 2008

Number of shared co-authors 1

Nina Fenouille

Universite Paris Cite, INSERM, CNRS

Career Start Year 2008

Number of shared co-authors 0

Lawrence N Kwong

The University of Texas MD Anderson Cancer Center

Career Start Year 2007

Number of shared co-authors 3

M Raza Zaidi

Northwell Health Cancer Institute

Career Start Year 2006

Number of shared co-authors 6

Chi-Ping Day

Center for Cancer Research, National Cancer Institute

Career Start Year 2002

Number of shared co-authors 5

Yongmei Feng

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Career Start Year 2002

Number of shared co-authors 3

Oscar M Tirado

Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)/CIBERONC

Career Start Year 2000

Number of shared co-authors 1

Christopher D Willey

University of Alabama at Birmingham

Career Start Year 2000

Number of shared co-authors 0

Yardena Samuels

Weizmann Institute of Science

Career Start Year 1998

Number of shared co-authors 6

Yaoqi Alan Wang

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 0

Jun Yao

The University of Texas MD Anderson Cancer Center

Career Start Year 1997

Number of shared co-authors 0

Andrew E Aplin

Thomas Jefferson University

Career Start Year 1996

Number of shared co-authors 4

Timothy A Chan

Cleveland Clinic.

Career Start Year 1994

Number of shared co-authors 1

Livio Trusolino

Candiolo Cancer Institute - FPO IRCCS

Career Start Year 1993

Number of shared co-authors 3

Jan Paul Medema

Oncode Institute

Career Start Year 1993

Number of shared co-authors 2

Ashani T Weeraratna

Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine

Career Start Year 1992

Number of shared co-authors 7

Marcus Bosenberg

Yale School of Medicine

Career Start Year 1992

Number of shared co-authors 5

Levi A Garraway

Broad Institute of Harvard and MIT

Career Start Year 1991

Number of shared co-authors 3

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 0

Lori S Hart

Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research

Career Start Year 1987

Number of shared co-authors 0

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 2

Daniel S Peeper

Netherlands Cancer Institute

Career Start Year 1987

Number of shared co-authors 5

Grant A McArthur

University of Melbourne

Career Start Year 1986

Number of shared co-authors 4

David E Fisher

Cutaneous Biology Research Center, Mass. General Hospital, Harvard Medical School

Career Start Year 1983

Number of shared co-authors 7

Ze'ev Ronai

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Career Start Year 1981

Number of shared co-authors 6

Francisca Vazquez

Broad Institute of MIT and Harvard

Career Start Year 1979

Number of shared co-authors 0

Meenhard Herlyn

Ellen and Ronald Caplan Cancer Center, The Wistar Institute

Career Start Year 1972

Number of shared co-authors 4

row(s) 1 - 30 of 30

Lukas Sommer

Institute of Anatomy, University of Zurich

Co-authored papers 10

Reinhard Dummer

University Hospital Zurich

Co-authored papers 7

Mitchell P Levesque

University Hospital Zurich

Co-authored papers 6

Phil F Cheng

University Hospital of Zurich

Co-authored papers 5

Olga Shakhova

Institute of Anatomy, University of Zurich

Co-authored papers 4

Simon M Schaefer

Institute of Anatomy, University of Zurich

Co-authored papers 4

Raffaella Santoro

University of Zurich

Co-authored papers 4

Jos Jonkers

Oncode Institute, Netherlands Cancer Institute

Co-authored papers 3

Julien Debbache

Institute of Anatomy, University of Zurich

Co-authored papers 3

Lodewyk F A Wessels

University Medical Centre Mannheim, University of Heidelberg

Co-authored papers 3

Michael Wegner

Institut fur Biochemie, Friedrich-Alexander-Universitat Erlangen-Nurnberg

Co-authored papers 2

Jessica H??usel

University Hospital Basel, University of Basel

Co-authored papers 2

Paolo Cinelli

Zurich University Hospital

Co-authored papers 2

Daniela Mihic-Probst

University Hospital Zurich

Co-authored papers 2

Holger Moch

University Hospital Zurich

Co-authored papers 2

Roger Stupp

Northwestern University

Co-authored papers 1

Siraj M Ali

Foundation Medicine

Co-authored papers 1

Timothy C Burn

Incyte Research Institute

Co-authored papers 1

Theresa Guo

Moores Cancer Center, University of California

Co-authored papers 1

Connie R Jimenez

Co-authored papers 1

Glenn Merlino

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 1

Claudia Matter

University Hospital Zurich, University of Zurich

Co-authored papers 1

Susan R Davis

Co-authored papers 1

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 1

Pravin J Mishra

Robert Wood Johnson Medical School, The State University of New Jersey

Co-authored papers 1

Edwin Cuppen

Hartwig Medical Foundation

Co-authored papers 1

Paul Erne

Biostatistics and Prevention Institute, University of Zurich

Co-authored papers 1

Paul S Meltzer

Center for Cancer Research, National Cancer Institute, National Institutes of Health